• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Avidity Biosciences Inc.

    11/13/24 4:40:35 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNA alert in real time by email
    SC 13G/A 1 rnaa3_111224.htm COWEN FINANCIAL PRODUCTS LLC rnaa3_111224.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*
    Avidity Biosciences, Inc
    (Name of Issuer)
    Common Stock
    (Title of Class of Securities)
    05370A108
    (CUSIP Number)
    September 30, 2024
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [   ] Rule 13d-1(b)
    [X] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 05370A108
           
    1
    NAME OF REPORTING PERSON
    Cowen Financial Products LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    27-0423711
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0%
    12
    TYPE OF REPORTING PERSON
    Passive Investor
    CUSIP No.: 05370A108
    ITEM 1(a). NAME OF ISSUER:
    Avidity Biosciences, Inc
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    10578 Science Center Drive
    Ste. 125
    San Diego, CA 92121
    ITEM 2(a). NAME OF PERSON FILING:
    Cowen Financial Products LLC
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    599 Lexington Ave.
    New York, NY 10022
    ITEM 2(c). CITIZENSHIP:
    Delaware
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common Stock
    ITEM 2(e). CUSIP NUMBER:
    05370A108
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [ ]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    0
    (b) Percent of class:
    0%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    0
    (ii) shared power to vote or to direct the vote:
    (iii) sole power to dispose or direct the disposition of:
    0
    (iv) shared power to dispose or to direct the disposition of:
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 05370A108
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    November 12 2024
    Cowen Financial Products LLC
    By:
    /s/ John Holmes
    Name:
    John Holmes
    Title:
    Chief Operating Officer
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $RNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RNA

    DatePrice TargetRatingAnalyst
    6/17/2025$55.00Outperform
    Wolfe Research
    6/11/2025$65.00Strong Buy
    Raymond James
    3/13/2025$70.00Buy
    Citigroup
    3/12/2025$72.00Outperform
    BMO Capital Markets
    3/7/2025$70.00Sector Outperform
    Scotiabank
    12/20/2024$72.00Buy
    H.C. Wainwright
    11/26/2024$67.00Outperform
    RBC Capital Mkts
    9/24/2024$59.00Buy
    Goldman
    More analyst ratings

    $RNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress

      -- FDA alignment on accelerated and full approval pathways for delpacibart braxlosiran (del-brax) in facioscapulohumeral muscular dystrophy (FSHD) -- -- Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center, and FORTITUDE trial investigator, will present topline del-brax data from dose escalation cohorts in oral presentation -- -- Stephen Tapscott, M.D., Ph.D., Professor of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, will highlight results on the characterization of a novel DUX4-regulated circulating biomarker in oral and poster presentations -- SAN DIEGO, June 11, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharm

      6/11/25 9:00:00 AM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants

      -- Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid and significant reduction in biomarkers -- -- Data support planned accelerated approval BLA submission in H2 2026 -- -- Data being presented at the 32nd Annual FSHD Society International Research Congress (IRC); Investor and analyst webcast event today, Monday, June 9 at 8:00 a.m. ET -- SAN DIEGO, June 9, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to prof

      6/9/25 7:01:00 AM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD

      -- Planning accelerated approval BLA submission in H2 2026, following topline data fromFORTITUDE™ biomarker cohort in Q2 2026 -- -- Initiated global, confirmatory Phase 3 FORWARD™ study of del-brax 2mg/kg every six weeks -- -- Investor and analyst webcast event today, Monday, June 9, 2025 at 8 a.m. ET -- SAN DIEGO, June 9, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced the accelerated approval regulatory pathway in the United States is open for delpacibart braxlosiran (del-brax) in the treatm

      6/9/25 7:00:00 AM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Program Officer Gallagher Kathleen P. sold $27,549 worth of shares (911 units at $30.24), decreasing direct ownership by 2% to 50,392 units (SEC Form 4)

      4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

      6/18/25 6:02:48 PM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Henig Noreen was granted 6,692 shares (SEC Form 4)

      4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

      6/12/25 6:42:47 PM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Boess Carsten was granted 6,692 shares (SEC Form 4)

      4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

      6/12/25 6:40:46 PM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care